TVTX (STOCKS)
Travere Therapeutics, Inc. Common Stock
$61.430000
-0.730000 (-1.17%)
Prev close: $62.160000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Eric M. Dube
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,546.65M
- Employees
- 385
- P/E (TTM)
- -81.39
- P/B (TTM)
- 238.72
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
11
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$0.06 | $-0.14 | +0.2015 | +142.40% |
|
Mar 2026 (Q1)
|
$-0.40 | $-0.27 | -0.1291 | -47.66% |
|
Dec 2025 (Q4)
|
$0.03 | $-0.12 | +0.1504 | +124.92% |
|
Sep 2025 (Q3)
|
$0.28 | $-0.21 | +0.4920 | +232.08% |
Financial Statements
| Revenues | $591.33M |
| Benefits Costs and Expenses | $658.41M |
| Cost Of Revenue | $8.26M |
| Costs And Expenses | $631.79M |
| Gross Profit | $583.07M |
| Nonoperating Income/Loss | -$26.62M |
| Operating Expenses | $623.53M |
| Selling, General, and Administrative Expenses | $364.51M |
| Other Operating Expenses | $259.01M |
| Operating Income/Loss | -$40.46M |
| Income/Loss From Continuing Operations After Tax | -$67.68M |
| Income/Loss From Continuing Operations Before Tax | -$67.07M |
| Income/Loss From Discontinued Operations Net Of Tax | $24.22M |
| Income Tax Expense/Benefit | $605.00K |
| Net Income/Loss | -$43.46M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$43.46M |
| Net Income/Loss Available To Common Stockholders, Basic | -$43.46M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.46 |
| Diluted Earnings Per Share | -$0.47 |
| Basic Average Shares | 274,943,302 |
| Diluted Average Shares | 288,331,442 |
| Assets | $799.36M |
| Current Assets | $615.14M |
| Inventory | $40.05M |
| Other Current Assets | $575.09M |
| Noncurrent Assets | $184.22M |
| Fixed Assets | $3.23M |
| Intangible Assets | $131.52M |
| Other Non-current Assets | $49.47M |
| Liabilities | $774.84M |
| Current Liabilities | $152.03M |
| Accounts Payable | $7.50M |
| Other Current Liabilities | $144.53M |
| Noncurrent Liabilities | $622.81M |
| Equity | $24.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $24.52M |
| Liabilities And Equity | $799.36M |
| Net Cash Flow From Operating Activities | $92.70M |
| Net Cash Flow From Operating Activities, Continuing | $92.70M |
| Net Cash Flow From Investing Activities | -$202.99M |
| Net Cash Flow From Investing Activities, Continuing | -$202.99M |
| Net Cash Flow From Financing Activities | $153.06M |
| Net Cash Flow From Financing Activities, Continuing | $153.06M |
| Exchange Gains/Losses | -$194.00K |
| Net Cash Flow | $42.58M |
| Net Cash Flow, Continuing | $42.78M |
| Comprehensive Income/Loss | -$43.77M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$43.77M |
| Other Comprehensive Income/Loss | -$43.77M |